Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
(n.d.-a)
26,27 Exposures to endocrine-disrupting chemical toxins such as herbicides and pesticides, compounds from plastics, heavy metals, natural gas and oil, radiofrequency electromagnetic radiation, air pollution, and noise pollution may directly impair testosterone and sperm production in addition to their effects on sperm DNA
The contrast agent is reported with code Q9950 (Injection, sulfur hexafluoride lipid microspheres, per mL)
DOSAGE Dosing for IGF-1 LR3 is based on anecdotal data and preclinical research, aiming for low-dose, infrequent administration due to the compound's potency and long half-life
For analytes at the lower limit, the lower limit of detection was used
